Table 2.
Univariate and multivariate analysis of variables associated with clinical remission at month-6.
| Variables | Remission at month-6 (n=36) | No remission at month-6 (n=32) | Univariate P-value | Multivariate P-value |
|---|---|---|---|---|
| Age (years) | 58.0 [46.0–67.7] | 58.5 [49.2–67.7] | 0.7 | |
| Gender (Female/Male) | 9/27 | 10/22 | 0.6 | |
| Weight (kg) at baseline* | 74.3 [66.0–82.0] | 77.3 [70.7-89.6] | 0.1 | 0.1 |
| UP (g/d) at baseline* | 5.0 [4.0–7.0] | 7.8 [5.8–12.2] | 0.0001 | 0.02 |
| Serum creatinine (µmol/L) at baseline | 119 [86–151] | 121 [87–163] | 0.7 | |
| Serum albumin (g/L) at baseline* | 25.5 [20.7–30.2] | 16.6 [12.5–23.0] | <0.0001 | 0.8 |
| CD19+ count (cell/µL) at baseline | 158.5 [112.8–277.5] | 208.0 [122.0–291.0] | 0.3 | |
| CD19+ count (cell/µL) at month-3* | 0.0 [0.0–2.7] | 3.0 [1.0–25.0] | 0.002 | 0.3 |
| Etiology | 0.2 | |||
| Anti-PLA2R1-associated pMN | 33 (92%) | 29 (91%) | ||
| Anti-THSD7A-associated pMN | 0 (0%) | 2 (6%) | ||
| Double negative patients | 3 (8%) | 1 (3%) | ||
| Anti-PLA2R1 Ab titer (RU/mL) at baseline* | 89 [21–173] | 218 [76–561] | 0.002 | 0.9 |
| Patient with RTX <2µg/mL at month-3* | 12 (33%) | 26 (81%) | <0.0001 | 0.007 |
*Variables with p < 0.1 in univariate analysis tested into the multivariate logistic regression model.
Anti-PLA2R1 Ab, anti-Phospholipase A2 Receptor 1 antibody; Anti-THSD7A Ab, anti-Thrombospondin Type 1 Domain Containing 7A antibody; pMN, primary membranous nephropathy; RTX, rituximab; UP, 24-hour urinary protein excretion.